Pay in 4 interest-free payments of $6.90 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
(Conference abstract reporting NA-931s efficacy in DIO mice: ~26% weight reduction, improved lipids, no muscle loss or serious adverse effects) (NA-931, a novel quadruple IGF-1, GLP-1 and GIP incretin receptor agonist reduces body weight without muscle loss | Obesity Conferences 2024 | Weight Management Conferences 2024 | Obesity Events 2024 | Weight Management Congress | Obesity Conference) (NA-931, a novel quadruple IGF-1, GLP-1 and GIP incretin receptor agonist reduces body weight without muscle loss | Obesity Conferences 2024 | Weight Management Conferences 2024 | Obesity Events 2024 | Weight Management Congress | Obesity Conference)
El nmero de personas inscritas en Medicare en los Estados Unidos equivale a 70.1 millones, el programa federal de seguro mdico para adultos de 65 aos o ms
Other Ingredients: Proprietary Lipid Blend (sunflower oil and palm oil), hydroxypropyl methylcellulose (vegetable capsule)
Phase 2 data showed weight loss exceeding 24% at the highest dose, surpassing both semaglutide and tirzepatide
